A sensational warning from America’s top vaccines official has sparked alarm, with a lengthy, argumentative memo to staff promising a sweeping overhaul of vaccine regulation. The claim? That at least 10 children died after Covid vaccination. Yet the memo offers no supporting evidence for this figure and provides only scant details about the proposed regulatory changes.
These top-down reforms, rolled out without input from outside advisers or public data, worry experts. They fear essential vaccines, including the flu shot, could be scaled back or disappear altogether, potentially eroding public trust in vaccination programs.
“Ultimately, this will lead to fewer vaccines and more vaccine-preventable illness,” warned Dan Jernigan, a longtime CDC scientist who recently left the National Center for Emerging and Zoonotic Infectious Diseases.
The 10 child deaths cited occurred in youths aged 7 to 16 between 2021 and 2024 and were allegedly reported to VAERS, a crowdsourced database open to public submissions. Vinay Prasad, director of the FDA’s Center for Biologics Evaluation and Research (CBER) and chief medical and scientific officer, claimed in the memo that the FDA would acknowledge Covid vaccines have “killed American children,” and questioned whether vaccines saved more healthy kids than they harmed.
However, Prasad did not provide any details about the cases—such as the specific conditions involved, how the deaths were linked to vaccination, or why initial assessments deemed the deaths unrelated and later reassessments contradicted them.
Paul Offit, an infectious diseases physician at Children’s Hospital of Philadelphia, pressed for evidence. “When making a sensational claim, it’s incumbent to back it with data,” he said, noting the memo did not supply such evidence.
The Covid vaccines have been administered to millions and are widely regarded as safe and effective. The memo’s assertions and the proposed regulatory approach diverge sharply from established FDA practices.
“I’ve never seen anything like this,” remarked Jernigan, who spent 31 years at the CDC and frequently collaborated with the FDA.
Sharing policy changes via email to all staff, without convening the Vaccines and Related Biological Products Advisory Committee (VRBPAC) or publishing data in a public format, is highly unusual, Jernigan added.
While the memo does not specify death causes, Prasad highlights myocarditis, a rare heart inflammation seen after vaccination. Yet myocarditis is far more common and severe with Covid infection, and vaccination reduces overall risk. If myocarditis contributed to any child deaths, autopsies—standard in unexplained pediatric deaths—would typically reveal such damage, according to Offit. Proving a vaccine-caused myocarditis rather than a virus-related one would be essential.
Tracy Beth Høeg, currently FDA senior advisor for clinical sciences, led the investigation over the summer, Prasad said. The memo also credits FDA Commissioner Marty Makary for identifying cases, and promises that new regulatory rules will prevent future searches like this.
Prasad asserted that the deaths are “certainly an underestimate” and that “the real number is higher,” though no evidence was provided to support that claim.
Responses from the health department and Prasad about evidence linking the deaths to Covid vaccination, or details on how vaccine-approval regulations would change, were not available at press time.
Reflecting on the vaccine era, Offit noted that the Covid vaccines represented a monumental scientific achievement under the prior administration. Now, to hear the head of CBER claim vaccines killed children, he said, is a striking reversal.
The White House did not comment on the allegations about vaccine-related child deaths.
Since the vaccine rollout began, officials emphasized transparent reporting of adverse events. As Covid emerged, reporting guidance intensified: physicians were urged to report potential side effects, and the public was informed about how to report symptoms via mechanisms like VAERS and the CDC’s V-safe program. The Vaccine Safety Datalink (VSD), which draws on medical records for roughly 10% of the population, has been a crucial tool for confirming signals seen in VAERS, such as the initial detection of myocarditis after vaccination and rare clotting events linked to certain vaccines.
Though the memo centers on Covid vaccines, it also nods to broader vaccine concerns common among anti-vaccine perspectives. Prasad argues that the FDA has not adequately weighed the benefits and harms of administering multiple vaccines concurrently, though no concrete harms are cited. He suggests changing guidelines on combining vaccines, but without presenting supporting evidence. Critics counter that concomitant vaccines have long been used without demonstrable harm, and altering regulatory standards without evidence could hinder vaccine deployment.
Regarding measles, mumps, and rubella (MMR) vaccines, Prasad notes that high community vaccination rates benefit even those who aren’t vaccinated, but it remains unclear whether reduced uptake would alter this dynamic.
The proposed regulatory shift would require randomized trials showing clinical outcomes (such as reduced illness) rather than relying solely on immune responses for new products. It would also overhaul the annual flu vaccine framework, including the surrogate markers previously used to gauge effectiveness.
Experts warn that for vaccines like the flu—and for Covid boosters—the proposed changes could pose practical challenges. Conducting year-by-year trials during flu season could render vaccines outdated by the time results are ready, potentially delaying crucial protection. Delays or reduced access to influenza vaccines could mean more preventable deaths, especially given a severe flu season on record.
Offit and others stress that undermining public confidence in vaccines is dangerous and irresponsible. The stakes are high, with hospitalized children and ongoing fatalities from the virus.
The resulting uncertainty makes it harder for the public and healthcare professionals to interpret evidence and trust health agencies’ guidance. As Jernigan notes, clarity and trust are increasingly hard to come by in this evolving landscape.
